Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT05974410 Available - Breast Cancer Clinical Trials

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Start date: n/a
Phase:
Study type: Expanded Access

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2023, 22 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma.

NCT ID: NCT05776160 Available - Follicular Lymphoma Clinical Trials

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Start date: n/a
Phase:
Study type: Expanded Access

The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.

NCT ID: NCT05619367 Available - Clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)

A Compassionate Use (CU) Program of Odronextamab

Start date: n/a
Phase:
Study type: Expanded Access

Provide compassionate use of odronextamab

NCT ID: NCT05215405 Available - Clinical trials for Relapsed Childhood Lymphoblastic Lymphoma

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL

Start date: n/a
Phase:
Study type: Expanded Access

The overall goal of this expanded access program is to provide Venetoclax and Navitoclax to patients with acute lymphocytic leukemia (ALL) or lymphoblastic lymphoma (LL) who have exhausted standard treatments.

NCT ID: NCT05172700 Available - Clinical trials for Waldenstrom Macroglobulinemia

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.